Press Room

Find news and updates from PhRMA, representing the country’s leading biopharmaceutical research companies. Our members are committed to finding tomorrow’s cures and treatments for some of the most serious diseases such as cancer, Alzheimer’s disease, cystic fibrosis and Parkinson’s.

Latest News from PhRMA

Nevada Addresses SB 539’s Most Significant Flaws

June 29, 2018

Judge James C. Mahan of the United States District Court for the District of Nevada entered an order yesterday dismissing without prejudice litigation brought by PhRMA and the Biotechnology Innovation Organization (BIO) against the State of Nevada.

Read More

New Analysis Shows Using ICER’s Value Assessments Would Limit Access to Life-Saving Medicines in Medicare Part B

May 31, 2018

If Medicare were to utilize one-size-fits-all value assessments like the Institute for Clinical and Economic Review’s (ICER) framework as the basis for coverage, 62 to 93 percent of patients with serious, complex conditions would face access barriers to life-saving medicines, according to a new analysis from Xcenda.

Read More

PhRMA Statement on President Trump’s Drug Pricing Blueprint

May 11, 2018

PhRMA president and CEO Stephen J. Ubl issued a statement on President Donald Trump’s drug pricing blueprint.

Read More

PhRMA Welcomes 2018 Special 301 Report

April 27, 2018

The Pharmaceutical Research and Manufacturers of America (PhRMA) welcomed the 2018 Special 301 Report, including a new section devoted to pharmaceutical market access barriers, released today by U.S. Trade Representative (USTR) Robert Lighthizer.

Read More

New “Let’s Talk About Cost” Ads Highlight How Copay Accumulator Programs Leave Patients Financially Exposed

March 27, 2018

PhRMA unveiled new advertisements highlighting how the use of copay accumulator programs by insurance companies and other middlemen could result in patients facing thousands of dollars in unexpected medical costs.

Read More

Analysis Finds Higher Outpatient Drug Spending At 340B Hospitals

March 14, 2018

A new analysis finds hospitals participating in the 340B Drug Discount Program have higher per patient outpatient pharmacy costs than their non-340B counterparts – meaning patients at 340B hospitals are prescribed more medicines and/or more expensive medicines.

Read More

Value-Based Contracts May Lower Patients’ Out-of-Pocket Costs by 28 Percent

February 26, 2018

In the past two years, commercially insured patients in health plans with value-based contracts for diabetes, high cholesterol and HIV medicines had copays that were, on average, 28 percent lower for those medicines compared to patients in other plans

Read More

PhRMA Statement on President’s FY2019 Budget

February 12, 2018

PhRMA president & CEO Stephen J. Ubl issued a statement on President Donald Trump’s FY2019 budget request.

Read More